Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell therapies for autoimmune diseases. The collaboration will bring together Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T cell receptors with Sonoma Biotherapeutics’ pioneering approach to developing and manufacturing gene-modified Treg cell therapies.
Latham & Watkins LLP advised Sonoma Biotherapeutics in the transaction with licensing deal team led by Bay Area partner Judith Hasko, with associates Robert Yeh, Kristina Funahashi and Xiaohan Wu, and a corporate deal team led by Mark Roeder, with associate Michelle Chern. Advice was also provided on tax matters by partner Kirt Switzer; and on data privacy matters by partner Heather Deixler.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
